{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-002145","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2023-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.698364+00:00","generated_at":"2026-06-20T01:02:04.139227+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Twist Bioscience Q1 FY2023 revenue $54.2M (+29% YoY), net loss narrows","bullets":["Revenue $54.2M, up 29% YoY; orders $64.7M, up 30% YoY.","Net loss of $41.8M ($0.74/share) improved from $45.6M ($0.91/share) YoY.","Cash and investments $438.7M; first products shipped from Wilsonville Factory of the Future.","Customer count 2,060 (up from ~1,800); gene shipments ~134,000 (vs ~125,000).","Launched NGS panels for rare disease; Astellas collaboration; biopharma partners at 278 with 95 active programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-002145","json":"https://secwatch.observer/filing/0001628280-23-002145.json","markdown":"https://secwatch.observer/filing/0001628280-23-002145.md","text":"https://secwatch.observer/filing/0001628280-23-002145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023002145/0001628280-23-002145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023002145/twist-20230203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T01:02:04.139227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9290e6df514aba6e592ab7b9bbf02243ce181e37","claim":"Twist Bioscience Corp reported first quarter of fiscal 2023 ended December 31, 2022 results: revenue $54.2 million, net income $41.8 million, EPS $0.74 per share.","evidence_excerpt":"• Revenue: Total revenues for the first quarter of fiscal 2023 were $54.2 million compared to $42.0 million for the same period of fiscal 2022 . • Cost of Revenues: Cost of revenues for the first quarter of fiscal 2023 was $29.4 million compared to $27.1 million for the same period of fiscal 2022 . • Research and Development Expenses: Research and development expenses for the first quarter of fiscal 2023 were $31.2 million compared to $22.6 million for the same period of fiscal 2022 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the first quarter of fiscal 2023 were $42.3 million compared to $51.1 million for the same period of fiscal 2022 . • Net Loss: Net loss attributable to common stockholders for the first quarter of fiscal 2023 was $41.8 million, or $0.74 per share, compared to $45.6 million, or $0.91 per share, for the same period of fiscal 2022 .","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023002145/0001628280-23-002145-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal 2023 ended December 31, 2022"},{"label":"Revenue","value":"$54.2 million"},{"label":"Net income","value":"$41.8 million"},{"label":"EPS","value":"$0.74 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}